JP2021169534A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021169534A5 JP2021169534A5 JP2021127278A JP2021127278A JP2021169534A5 JP 2021169534 A5 JP2021169534 A5 JP 2021169534A5 JP 2021127278 A JP2021127278 A JP 2021127278A JP 2021127278 A JP2021127278 A JP 2021127278A JP 2021169534 A5 JP2021169534 A5 JP 2021169534A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- platin
- composition according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 49
- 238000011282 treatment Methods 0.000 claims 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 9
- 238000011287 therapeutic dose Methods 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229940123237 Taxane Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 238000011221 initial treatment Methods 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 210000003708 urethra Anatomy 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229950007221 nedaplatin Drugs 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326144P | 2016-04-22 | 2016-04-22 | |
| US62/326,144 | 2016-04-22 | ||
| JP2018555499A JP6928000B2 (ja) | 2016-04-22 | 2017-04-21 | 化学療法の改善 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555499A Division JP6928000B2 (ja) | 2016-04-22 | 2017-04-21 | 化学療法の改善 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021169534A JP2021169534A (ja) | 2021-10-28 |
| JP2021169534A5 true JP2021169534A5 (enExample) | 2022-01-06 |
| JP7193591B2 JP7193591B2 (ja) | 2022-12-20 |
Family
ID=60115481
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555499A Expired - Fee Related JP6928000B2 (ja) | 2016-04-22 | 2017-04-21 | 化学療法の改善 |
| JP2021127278A Active JP7193591B2 (ja) | 2016-04-22 | 2021-08-03 | 化学療法の改善 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555499A Expired - Fee Related JP6928000B2 (ja) | 2016-04-22 | 2017-04-21 | 化学療法の改善 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190117620A1 (enExample) |
| EP (2) | EP4035667A1 (enExample) |
| JP (2) | JP6928000B2 (enExample) |
| AU (2) | AU2017254774B2 (enExample) |
| CA (1) | CA3058505A1 (enExample) |
| WO (1) | WO2017181242A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190282540A1 (en) * | 2016-04-06 | 2019-09-19 | Noxopharm Limited | Targeted drug delivery |
| JP2019513826A (ja) | 2016-04-06 | 2019-05-30 | ノクソファーム リミティド | 放射線療法の改善 |
| CA3058503A1 (en) | 2016-04-06 | 2017-10-12 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
| US20190117620A1 (en) * | 2016-04-22 | 2019-04-25 | Noxopharm Limited | Chemotherapy improvements |
| JP2023519990A (ja) | 2020-03-30 | 2023-05-15 | ノクソファーム リミティド | 感染に関連する炎症の治療のための方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| US8178123B2 (en) * | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| AU2002951833A0 (en) * | 2002-10-02 | 2002-10-24 | Novogen Research Pty Ltd | Compositions and therapeutic methods invloving platinum complexes |
| JP2007525485A (ja) | 2003-11-19 | 2007-09-06 | ノボゲン リサーチ ピーティーワイ リミテッド | 複合的な放射線治療及び化学治療の組成物及び方法 |
| EP2436680B1 (en) * | 2004-09-21 | 2016-05-18 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
| US20190117620A1 (en) | 2016-04-22 | 2019-04-25 | Noxopharm Limited | Chemotherapy improvements |
-
2017
- 2017-04-21 US US16/094,925 patent/US20190117620A1/en not_active Abandoned
- 2017-04-21 AU AU2017254774A patent/AU2017254774B2/en not_active Ceased
- 2017-04-21 JP JP2018555499A patent/JP6928000B2/ja not_active Expired - Fee Related
- 2017-04-21 EP EP22163870.3A patent/EP4035667A1/en not_active Withdrawn
- 2017-04-21 EP EP17785173.0A patent/EP3445347B1/en not_active Not-in-force
- 2017-04-21 WO PCT/AU2017/050363 patent/WO2017181242A1/en not_active Ceased
- 2017-04-21 CA CA3058505A patent/CA3058505A1/en not_active Abandoned
-
2021
- 2021-08-03 JP JP2021127278A patent/JP7193591B2/ja active Active
- 2021-11-11 AU AU2021266308A patent/AU2021266308B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021169534A5 (enExample) | ||
| JP2022022264A5 (enExample) | ||
| JP2023002662A5 (enExample) | ||
| JP5911929B2 (ja) | 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬 | |
| JP2017516802A5 (enExample) | ||
| JP2024133474A5 (enExample) | ||
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| RU2012157805A (ru) | Способы лечения рака мочевого пузыря | |
| JP2014512356A5 (enExample) | ||
| JP2020517696A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| JP2019513812A5 (enExample) | ||
| JP2023116697A5 (enExample) | ||
| TWI441639B (zh) | 用於治療卵巢癌之包含紫杉醇之組合 | |
| AU2017205749B2 (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
| JP2021169534A (ja) | 化学療法の改善 | |
| RU2011151854A (ru) | Новые терапевтические способы применения инекальцитола | |
| RU2017137008A (ru) | Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени | |
| RU2015126505A (ru) | Применение и способы лечения заболеваний и патологических состояний печени | |
| JP2020520385A5 (enExample) | ||
| JP2011514356A5 (enExample) | ||
| AU2002251763B2 (en) | Method for treating cancer | |
| JP2005509663A5 (enExample) | ||
| JPWO2020037152A5 (enExample) | ||
| RU2007111685A (ru) | Применение 9-оксоакридин-10-уксусной кислоты и/или ее соли в комбинации с антиэстрогеном и/или прогестином для лечения этрогензависимых опухолей, способ лечения и наборы |